The Role of Cytoreductive Surgery in Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 791

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Interests: CRS/HIPEC; cancer

Special Issue Information

Dear Colleagues,

This Special Issue "The Role of Cytoreductive Surgery in Cancers" explores the significance and impact of cytoreductive surgery on various types of cancer. This collection of articles delves into this surgical approach and its outcomes. It focuses on the role of cytoreduction in improving the survival rates, reducing the tumor burden, and enhancing the effectiveness of other treatment modalities, such as chemotherapy and radiation therapy. We also discuss the challenges and limitations associated with cytoreductive surgery, as well as the potential strategies employed to overcome them. Overall, this Special Issue provides valuable insights into the evolving field of cytoreductive surgery and its potential to revolutionize cancer treatment by targeting the primary tumor site and minimizing the risk of metastasis.

Dr. Andreas Bremers
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor metastasis
  • cytoreductive surgery (CRS)
  • hyperthermic intraperitoneal chemotherapy (HIPEC)
  • cytoreductive surgery
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 377 KiB  
Article
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Sarcomatosis
by Can Yurttas, Ruth Ladurner, André L. Mihaljević and Jens Strohäker
Cancers 2024, 16(17), 3034; https://doi.org/10.3390/cancers16173034 - 30 Aug 2024
Viewed by 467
Abstract
(1) Background: Cytoreductive surgery (CRS) with HIPEC is considered the standard of care for selected patients with peritoneal carcinomatosis, but evidence-based treatment recommendations for the therapy of peritoneal sarcomatosis are scarce. (2) Methods: We retrospectively analyzed all adult patients treated with CRS and [...] Read more.
(1) Background: Cytoreductive surgery (CRS) with HIPEC is considered the standard of care for selected patients with peritoneal carcinomatosis, but evidence-based treatment recommendations for the therapy of peritoneal sarcomatosis are scarce. (2) Methods: We retrospectively analyzed all adult patients treated with CRS and HIPEC for peritoneal sarcomatosis between 2017 and 2024. (3) Results: Ten patients with a median age of 46.1 years (range: 23–77 years) with metachronous (40%) or synchronous (60%) peritoneal sarcomatosis from six different tumor entities were treated according to tumor board recommendation using CRS and HIPEC with cisplatin and doxorubicin over 60 min at 42.0 °C. The length of stay in the intensive care unit and hospital was 1.24 (0.6–1.9 days) and 11.1 days (6–17 days), respectively. Complete cytoreduction was achieved in 90% of the patients, with a median PSI of 11.5. Postoperative complications occurred in five cases, but no surgical revisions were necessary, and no acute kidney damage was recorded. (4) Conclusions: CRS with HIPEC in the presence of peritoneal sarcomatosis could be safely performed in our collective. Whether this resulted in an oncological treatment benefit cannot be concluded in view of the heterogeneous and small collective. Therefore, larger and prospective studies are warranted. Full article
(This article belongs to the Special Issue The Role of Cytoreductive Surgery in Cancers)
Show Figures

Figure 1

Back to TopTop